A chiral electrokinetic chromatography method for the separation and quantitation of licarbazepine and licarbazepine acetate in pharmaceutical formulations and urine samples
S-Licarbazepine acetate is a new antiepileptic that is quickly metabolized to S-licarbazepine which is the active principle. In this study, an enantioselective methoddology enabling the simultaneous separation of licarbazepine acetate and licarbazepine by Electrokinetic Chromatography has been devel...
| Autores: | , , |
|---|---|
| Tipo de recurso: | artículo |
| Fecha de publicación: | 2023 |
| País: | España |
| Institución: | Universidad de Alcalá (UAH) |
| Repositorio: | e_Buah Biblioteca Digital Universidad de Alcalá |
| Idioma: | inglés |
| OAI Identifier: | oai:ebuah.uah.es:10017/59849 |
| Acceso en línea: | http://hdl.handle.net/10017/59849 https://dx.doi.org/10.1016/j.talanta.2022.124020 |
| Access Level: | acceso abierto |
| Palabra clave: | Cyclodextrin Electrokinetic chromatography Enantiomeric separation Licarbazepine Pharmaceutical formulation Urine. Química Chemistry |
| Sumario: | S-Licarbazepine acetate is a new antiepileptic that is quickly metabolized to S-licarbazepine which is the active principle. In this study, an enantioselective methoddology enabling the simultaneous separation of licarbazepine acetate and licarbazepine by Electrokinetic Chromatography has been developed for the first time. After evaluating the potential of different chiral selectors, including bile salts and cyclodextrins, and selecting carboxymethyl-?-cyclodextrin as the most appropriate, a Box-Behnken experimental design was effectively applied for the optimization of the experimental separation conditions. Employing the best conditions, the four enantiomers were simultaneously separated (resolution values > 2.4) in less than 7 min. The evaluation of the figures of merit of the developed methodology showed to be suitable to determine both compounds. Finally, the EKC method was successfully applied in three different studies: (i) the quality control of the enantiopure pharmaceutical formulation, (ii) the monitoring of the stability and gastrointestinal digestion of the pharmaceutical formulation through a hydrolysis study, and (iii) the determination of licOH enantiomers in urine samples. |
|---|